Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification

Gottfried E. Konecny, Boris Winterhoff, Chen Wang

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Microarray-based gene expression studies demonstrate that ovarian cancer is both a clinically diverse and molecularly heterogeneous disease compromising subtypes with distinct gene expression patterns that are each associated with statistically significant different clinical outcomes. The information provided by gene expression based assays is promising and deserves incorporation into clinical decision-making. Further studies are needed to determine which subtype signatures are most appropriate to select patients for a given therapy. This process will require the development of standardized molecular diagnostic assays that can be used for retrospective correlative studies and prospective validations of their clinical utility. Recent advances in assay development for FFPE tissues will facilitate accurate and cost-effective classification of ovarian cancer and help move the evolving molecular classification to clinic. The current review will summarize the development of gene expression based assays in ovarian cancer and will describe how the results of studies to date have expanded our appreciation of the heterogeneity of ovarian cancer. We discuss difficulties in the development and validation of molecular classifications in ovarian cancer and we provide future directions how we may be able to soon classify the disease in a manner that might have greater clinical utility.

Original languageEnglish (US)
Pages (from-to)379-385
Number of pages7
JournalGynecologic Oncology
Volume141
Issue number2
DOIs
StatePublished - May 1 2016

Fingerprint

Transcriptome
Ovarian Neoplasms
Gene Expression
Molecular Pathology
Retrospective Studies
Costs and Cost Analysis
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Gene-expression signatures in ovarian cancer : Promise and challenges for patient stratification. / Konecny, Gottfried E.; Winterhoff, Boris; Wang, Chen.

In: Gynecologic Oncology, Vol. 141, No. 2, 01.05.2016, p. 379-385.

Research output: Contribution to journalReview article

Konecny, Gottfried E. ; Winterhoff, Boris ; Wang, Chen. / Gene-expression signatures in ovarian cancer : Promise and challenges for patient stratification. In: Gynecologic Oncology. 2016 ; Vol. 141, No. 2. pp. 379-385.
@article{70e66020ce2c48b991ce39d53f57b582,
title = "Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification",
abstract = "Microarray-based gene expression studies demonstrate that ovarian cancer is both a clinically diverse and molecularly heterogeneous disease compromising subtypes with distinct gene expression patterns that are each associated with statistically significant different clinical outcomes. The information provided by gene expression based assays is promising and deserves incorporation into clinical decision-making. Further studies are needed to determine which subtype signatures are most appropriate to select patients for a given therapy. This process will require the development of standardized molecular diagnostic assays that can be used for retrospective correlative studies and prospective validations of their clinical utility. Recent advances in assay development for FFPE tissues will facilitate accurate and cost-effective classification of ovarian cancer and help move the evolving molecular classification to clinic. The current review will summarize the development of gene expression based assays in ovarian cancer and will describe how the results of studies to date have expanded our appreciation of the heterogeneity of ovarian cancer. We discuss difficulties in the development and validation of molecular classifications in ovarian cancer and we provide future directions how we may be able to soon classify the disease in a manner that might have greater clinical utility.",
author = "Konecny, {Gottfried E.} and Boris Winterhoff and Chen Wang",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.ygyno.2016.01.026",
language = "English (US)",
volume = "141",
pages = "379--385",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Gene-expression signatures in ovarian cancer

T2 - Promise and challenges for patient stratification

AU - Konecny, Gottfried E.

AU - Winterhoff, Boris

AU - Wang, Chen

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Microarray-based gene expression studies demonstrate that ovarian cancer is both a clinically diverse and molecularly heterogeneous disease compromising subtypes with distinct gene expression patterns that are each associated with statistically significant different clinical outcomes. The information provided by gene expression based assays is promising and deserves incorporation into clinical decision-making. Further studies are needed to determine which subtype signatures are most appropriate to select patients for a given therapy. This process will require the development of standardized molecular diagnostic assays that can be used for retrospective correlative studies and prospective validations of their clinical utility. Recent advances in assay development for FFPE tissues will facilitate accurate and cost-effective classification of ovarian cancer and help move the evolving molecular classification to clinic. The current review will summarize the development of gene expression based assays in ovarian cancer and will describe how the results of studies to date have expanded our appreciation of the heterogeneity of ovarian cancer. We discuss difficulties in the development and validation of molecular classifications in ovarian cancer and we provide future directions how we may be able to soon classify the disease in a manner that might have greater clinical utility.

AB - Microarray-based gene expression studies demonstrate that ovarian cancer is both a clinically diverse and molecularly heterogeneous disease compromising subtypes with distinct gene expression patterns that are each associated with statistically significant different clinical outcomes. The information provided by gene expression based assays is promising and deserves incorporation into clinical decision-making. Further studies are needed to determine which subtype signatures are most appropriate to select patients for a given therapy. This process will require the development of standardized molecular diagnostic assays that can be used for retrospective correlative studies and prospective validations of their clinical utility. Recent advances in assay development for FFPE tissues will facilitate accurate and cost-effective classification of ovarian cancer and help move the evolving molecular classification to clinic. The current review will summarize the development of gene expression based assays in ovarian cancer and will describe how the results of studies to date have expanded our appreciation of the heterogeneity of ovarian cancer. We discuss difficulties in the development and validation of molecular classifications in ovarian cancer and we provide future directions how we may be able to soon classify the disease in a manner that might have greater clinical utility.

UR - http://www.scopus.com/inward/record.url?scp=84958259845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958259845&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2016.01.026

DO - 10.1016/j.ygyno.2016.01.026

M3 - Review article

C2 - 26827964

AN - SCOPUS:84958259845

VL - 141

SP - 379

EP - 385

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -